Alivus Life Sciences Limited — Investor Meet, 31-10-2024: Analysts/Institutional Investor Meet/Con. Call Updates

Glenmark Life Sciences Limited reported Q2 FY25 revenues of INR 507 crores, down 14.9% YoY, primarily due to temporary production halts. Despite challenges, the company achieved gross margins of 55.6% and anticipates stronger performance in the second half, driven by a robust order book and new product launches. EBITDA margin stood at 28.2%, and the company remains optimistic on growth, projecting high single-digit revenue increases for the fiscal year. The capacity expansions at Ankleshwar and Dahej are also expected to boost future production.